Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: A cohort study using The Health Improvement Network (THIN) primary care data by O'Keeffe, AG et al.
© 2016 O’Keeffe et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Clinical Epidemiology 2016:8 123–132
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
123
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CLEP.S104258
Time trends in the prescription of statins for the 
primary prevention of cardiovascular disease in 
the United Kingdom: a cohort study using The 
Health Improvement Network primary care data
Aidan G O’Keeffe1
Irwin Nazareth2
Irene Petersen2
1Department of Statistical Science, 
2Department of Primary Care and 
Population Health, University College 
London, London, UK
Background: Statins are widely prescribed for the primary prevention of cardiovascular disease. 
Guidelines exist for statin prescriptions, but there is little recent analysis concerning prescription 
trends over time and how these vary with respect to demographic variables.
Methods and results: Using The Health Improvement Network primary care database, statin 
therapy initiation and statin prescription prevalence rates were calculated using data from 
7,027,711 individuals across the UK for the years 1995 to 2013, overall and stratified by sex, 
age group, and socioeconomic deprivation level (Townsend score). Statin therapy initiation rates 
rose sharply from 1995 (0.51 per 1,000 person-years) up to 2006 (19.83 per 1,000 person-years) 
and thereafter declined (10.76 per 1,000 person-years in 2013). Males had higher initiation rates 
than females and individuals aged 60–85 years had higher initiation rates than younger or more 
elderly age groups. Initiation rates were slightly higher as social deprivation level increased, 
after accounting for age and sex. Prescription prevalence increased sharply from 1995 (2.36 
per 1,000 person-years) to 2013 (128.03 per 1,000 person-years) with males generally having a 
higher prevalence rate, over time, than females. Prevalence rates over time were generally higher 
for older age groups but were similar with respect to social deprivation level.
Conclusion: The uptake of statins within UK primary care has increased greatly over time 
with statins being more commonly prescribed to older patients in general and, in recent years, 
males appear to have been prescribed statins at higher rates than females. After accounting 
for age and sex, the statin therapy initiation rate increases with the level of social deprivation.
Keywords: cardiovascular disease, primary prevention, statin therapy, time trend, United 
Kingdom
Introduction
Statins – a large class of cholesterol-lowering drugs – are widely prescribed for the 
primary prevention of cardiovascular disease (CVD).1,2 Since the 1990s, a number of 
clinical trials and large-scale studies have demonstrated the effectiveness of statins for 
CVD prevention3–6 and, in recent years, statins have become one of the most regularly 
prescribed medicines in the UK.7 In January 2006, the UK government’s National 
Institute for Health and Care Excellence (NICE) issued guidelines suggesting that 
statins should be prescribed by general practitioners (GPs – UK family doctors) to 
adults aged under 75 years whose risk of developing CVD within 10 years exceeds 
20%.8 Generally, the 10-year risk of developing CVD is calculated using an  established 
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risk prediction method, such as the Framingham risk score9 
or QRISK/QRISK2 risk calculators.10–12 In July 2014, this 
guideline was adjusted, with the statin prescription risk 
score threshold reduced to a risk of 10%. For the over 75s, 
the same NICE guidelines have recommended that statin 
prescriptions should be considered irrespective of the 10-year 
CVD risk score.
Clearly, statins have been commonly prescribed in the UK 
and the NICE guidelines have recommended their use for a 
wide section of the UK population. However, despite this, 
few studies have investigated the rate at which statin therapy 
is initiated, the prevalence of statin prescriptions, and how 
these may have changed over time. Some studies on trends in 
statins prescription in the UK were undertaken during the late 
1990s and early 2000s, mainly using small data sources.13–16 
Other past works have examined statin prescription trends 
within Europe,17–24 Canada,25 and the US,26–28 though, again, 
with either relatively small cohorts or not with the aim of 
examining statin prescription trends over time.
In this study, we attempt a comprehensive, large-scale 
assessment of prescribing trends for statins over time within 
the UK. We examine both the rate of statin therapy initiation 
(the rate at which subjects begin the use of statins) and the 
prevalence of statin prescriptions over time for the primary 
prevention of CVD. In addition, we examine possible dif-
ferences in trends over time with respect to sex, age group, 
and level of socioeconomic deprivation. We use data from a 
large cohort of individuals that are generally representative 
of the UK population and have been collected over a long 
time period from 1995 to 2013.
Data and methodology
Data source
We used data from The Health Improvement Network (THIN) 
(www.epic-uk.org), a large-scale source of primary care data 
that is generally considered to be representative of the UK 
population.29,30 Approval for the use of THIN data for this 
research was granted by the Cegedim Strategic Data Medical 
Research UK Scientific Review Committee in August 2014 
(approval number: 14-021). Because this study was based on 
data extracted from THIN, it was exempt from human subjects 
review, and members of the study population did not have to 
provide written informed consent. THIN data contain informa-
tion on patient demographics alongside consultation informa-
tion and diagnoses (indexed using Read codes)31 and patient 
prescription records. Data in THIN are linked longitudinally for 
each patient, which facilitates analyses of trends over time. Fur-
thermore, THIN data include information on Townsend score, 
a measure of social deprivation using unemployment level, 
car ownership, home ownership, and household overcrowding 
levels to estimate the possible level of social deprivation within 
a particular postcode. Patients’ Townsend scores are categorized 
into five quintiles from 1 (least socioeconomic deprivation) to 
5 (most socioeconomic deprivation).
Study participants
We used data from general practices after the date at which 
they had adopted adequate methods for mortality reporting 
(acceptable mortality rate)32 and had a sufficiently developed 
computer system in use for patient data to be included in 
THIN (acceptable computer usage date).33 The study is on 
the use of statins for the primary prevention of CVD and, 
as such, only patients who had not previously experienced a 
CVD event were included in the cohort.
For analyses on the initiation of statin therapy, patients 
were included in the cohort from the earliest of: January 1, 
1995, their 18th birthday, or registration with the practice 
until the earliest of: death, first CVD event, transfer from 
GP practice, first statin prescription, or December 31, 2013. 
Patients who initiated statins within 6 months of practice reg-
istration were excluded from analyses concerning initiation of 
statin therapy. This was done to ensure that patients who had 
moved GP practice but who had previously received statins 
would not be included. The use of such a 6-month “qualifi-
cation period” has been routine in other studies concerning 
prescription trends using THIN data.34–36 For analyses on the 
prevalence of statin prescriptions, a 6-month qualification 
period was not used and patients were followed from cohort 
entry and beyond their first statin prescription.
Statistical analysis
Initiation of statin therapy
We estimated the statin therapy initiation rate, that is, the 
rate of first statin prescription, per 1,000 person-years for 
each calendar year, over a time period from 1995 to 2013. 
Statin therapy initiation rates were estimated using data 
from all practices combined and also stratified by sex, age 
group, and Townsend deprivation score. Poisson regression 
models were used to estimate statin initiation rates, with log 
(person-years at risk) as an offset term, for each calendar 
year (1995–2013). We performed separate univariate analy-
ses with each of: sex, age group, and Townsend score as 
explanatory variables and an overall multivariable analysis 
involving all of these variables. Age groups (in years) were 
classified as 18–34, 35–49, 50–59, 60–69, 70–74, 75–84, 
and ≥85.
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Prevalence of statin prescriptions
We estimated the prevalence of statin prescription by consid-
ering “episodes” during which a given patient was receiving 
regular statin prescriptions. For each patient, a statin prescrip-
tion episode occurs for a time period where statins were pre-
scribed at least every 273 days (approximately equivalent to 9 
months). A maximum time between successive prescriptions 
of 9 months was used since statins tend not to be prescribed 
for >6 months before a repeat prescription is issued. For each 
patient, in each calendar year of the cohort, the time periods 
during which a statin prescription episode occurs were cal-
culated and summed over all to give an overall time during 
which patients were receiving statins for each year. We call 
this the “statin prescription time”. The time “at risk” (ie, the 
overall time for which patients were eligible to receive statins 
in each calendar year) was calculated and the statin prescrip-
tion time was divided by the at risk time for each calendar 
year (and stratified by sex, age group, and Townsend score 
quintile, where appropriate) to calculate overall estimates of 
statin prescription  prevalence. Statin prescription prevalence 
rates were rescaled and reported per 1,000 person-years.
Data manipulation and extraction were performed using 
Stata (version 14), with data analysis undertaken in R 
 (version 3.1.2).
Results
Statin therapy initiation
Overall, there were 6,732,469 patients in our study of statin 
therapy initiation analyses of whom slightly more were 
female than male (52.3% and 47.7% of the cohort, respec-
tively). The number of patients in each of the Townsend score 
quintiles 1 to 4 was broadly similar with fewer patients in 
the most deprived, fifth, Townsend score quintile (Table 1). 
This distribution is in line with that of Blak et al.30  Overall, 
statin therapy initiation rates rose at an increasing rate 
from 1995 (initiation rate =0.51 per 1,000 person-years) to 
2004 (initiation rate =16.32 per 1,000 person-years), with a 
sharp peak at 2006 (initiation rate =19.83 per 1,000 person 
years), followed by a steady decline up to 2011 (initiation 
rate =10.88 per 1,000 person years) and, since 2011, rates 
have remained fairly constant (Figure 1A; Table 2). Where 
initiation rates are stratified by sex (Figure 1B; Table 2), a 
similar overall pattern is seen, although notably, since 2004, 
there appears to be a separation between males and females 
in that females generally have a slower rate of statin therapy 
initiation than males.
When statin therapy initiation rates were stratified by age 
group (Figure 1C), the rates remain low over time for those 
aged under 50 years, compared to other age groups, with the 
maximum statin therapy initiation rates (per 1,000 person 
years) of 0.83 for the 18–34 years age group (in 2005) and 
7.88 for the 35–49 years age group (in 2006). For the 50–59 
years age group, the rates are higher, in general, over time, 
approximately following a similar pattern to that seen in 
Figure 1A with an increase from 1995 (initiation rate =0.95 
per 1,000 person-years) to 2006 (initiation rate =30.12 per 
1,000 person-years) and a general decrease from 2007 to 
2011 (initiation rate =17.95 per 1,000 person-years), with 
rates remaining steady since 2011. The 70–74 years age 
group has the highest statin therapy initiation rate for each 
year overall, with the maximum statin therapy initiation 
rate occurring in 2006 (initiation rate =80.42 per 1,000 
person years). The 60–69 years and 75–84 years age groups 
also have high statin therapy initiation rates in each year, 
with maximum initiation rates (per 1,000 person years) of 
61.90 and 51.01, respectively, in 2006. In contrast, statin 
therapy initiation rates were considerably lower for those 
in the 85 years and over age group, in each calendar year, 
with a maximum initiation rate of 23.45 per 1,000 person 
years in 2006.
Stratified by Townsend score quintile (Figure 1D), the 
initiation rates follow the same general pattern over time as 
the overall rates (Figure 1A), though there do not appear to 
be any obvious differences in initiation rates between the 
different Townsend score quintiles.
After adjusting for other demographic variables (multi-
variable model in Table 3), females were ~24% less likely to 
initiate statins than males (initiation rate ratio [IRR] and cor-
responding 95% confidence interval 0.76 [0.762 to 0.772]).
For age groups, relative to a fixed rate of 1 in the 50–59 
years group, some age groups show comparably higher 
estimates (60–69 years: IRR 1.99 [1.973 to 2.002], 70–74 
Table 1 Demographics of the cohort for the initiation of statin 
therapy study
Total number of patients 6,732,469
Sex Male 3,211,813 (47.7%)
Female 3,520,656 (52.3%)
Townsend score quintile 1 (least deprived) 1,566,745 (23.3%)
2 1,384,301 (20.6%)
3 1,444,198 (21.4%)
4 1,359,639 (20.2%)
5 (most deprived) 977,586 (14.5%)
Mean age at start of observation 39.2 years
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years: IRR 2.48 [2.546 to 2.504], and 75–84 years: IRR 1.57 
[1.552 to 1.585]). Other age groups show comparably lower 
estimates (18–34 years IRR: 0.029 [0.028 to 0.029], 35–49 
years: IRR 0.283 [0.281 to 0.286], and ≥85 years: IRR 0.69 
[0.675 to 0.705]). For the Townsend score quintiles, IRR 
estimates, relative to the reference group of Townsend score 
quintile 1, were similar for quintiles 2 to 5, with estimates 
ranging from 0.98 (quintiles 3 and 4) to 1.03 (quintile 2) 
(univariable model in Table 3). However, after accounting 
for age group and sex (multivariable model in Table 3), 
the IRR estimates in the multivariable model increase with 
Townsend score quintile, with IRR estimates of: 1.05 (1.039 
to 1.056), 1.14 (1.131 to 1.150), 1.26 (1.251 to 1.273), and 
1.39 (1.372 to 1.399) for Townsend score quintiles 2, 3, 4, 
and 5, respectively.
Prevalence of statin prescriptions
We consider results for the estimation of the prevalence 
of statin prescriptions. Table 4 shows a summary of the 
patients considered in the analysis of statin prevalence. 
Figure 1 Plots showing the estimated statin therapy initiation rates from 1995 to 2013.
Note: (A) Overall, (B) stratified by sex, (C) stratified by age group, and (D) stratified by Townsend score quintile.
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Overall, statin prescription prevalence was low in 1995 
(prescription rate =2.36 per 1,000 person years) but rose 
slowly up to 2001 (prescription rate =22.41 per 1,000 per-
son years), after which there was an exponential increase in 
prevalence up to 2007 (96.53 per 1,000 person years). Since 
2007, although the statin prescription rate rises, the rate of 
increase has slowed somewhat (Figure 2A; Table 5). This 
same pattern is repeated for males and females separately 
(Figure 2B; Table 5), but we note that, since 2001, the rate of 
increase in prevalence in females has generally lagged behind 
that for males and the difference in prescription prevalence 
between males and females appears to be on the increase. 
This shift between males and females is similar to that seen 
for the statin therapy initiation rate in Figure 1B.
When statin prescription prevalence is stratified by age 
group (Figure 2C), prescription prevalence remains very low 
for the 18–34 age group, with a maximum prescription preva-
lence of 1.88 per 1,000 person years in 2008. For the 35–49 
age group, prescription prevalence has tended to remain low, 
although the rate has risen in more recent years, increasing 
from 7.25 per 1,000 person-years in 2001 to 30.90 per 1,000 
person-years in 2013. The change in the statin prescription 
rate has been more substantial for the 50–59 years age group, 
for whom prescription prevalence has increased from 4.96 
per 1,000 person-years in 1995 to 131.56 per 1,000 person-
years in 2013.
The oldest age groups (60–69, 70–74, 75–84, 85 and 
over) have experienced the greatest increase in statin pre-
scription rate from 1995 to 2013. A sharp increase in the 
prescription rate was observed for each age group between 
2000 and 2008. Since 2008, the increase in prescription 
prevalence has slowed slightly for the younger 60–69 years 
and 70–74 years age groups, with changes from 2008 to 
2013 (per 1,000 person-years) of 264.00 to 305.18 and 
392.15 to 453.77, respectively. In contrast, the prescription 
prevalence rate has continued to increase sharply for the 
75–84 years and 85 years and over age groups with changes 
Table 2 Table showing statin therapy initiation rates for all 
patients and for males and females separately from 1995 to 2013 
per 1,000 person-years
Year Statin therapy initiation rate
(per 1,000 person years)
All patients Males Females
1995 0.51 0.51 0.52
1996 1.44 1.29 1.59
1997 1.97 1.87 2.06
1998 2.31 2.24 2.37
1999 3.09 2.93 3.24
2000 4.28 4.29 4.27
2001 6.39 6.60 6.19
2002 9.07 9.39 8.77
2003 11.92 12.61 11.27
2004 16.32 16.66 15.99
2005 16.55 17.39 15.76
2006 19.83 21.24 18.49
2007 16.38 17.98 14.86
2008 16.14 17.88 14.50
2009 15.25 17.43 13.21
2010 12.45 14.11 10.91
2011 10.88 12.32 9.54
2012 11.38 12.66 10.20
2013 10.76 11.87 9.74
Table 4 Demographics of the cohort for the prevalence of statin 
therapy study
Total number of patients 7,027,711
Sex Male 3,356,438 (47.8%)
Female 3,671,273 (52.2%)
Townsend score quintile: 1 (least deprived) 1,633,640 (23.2%)
2 1,446,584 (20.6%)
3 1,506,846 (21.4%)
4 1,417,595 (20.2%)
5 (most deprived) 1,023,046 (14.6%)
Mean age at start of observation 39.8 years
Table 3 Results from univariable and multivariable analyses, 
estimating the relative statin therapy initiation rates, adjusted for 
time, with regard to sex, age group, and Townsend score quintile
Variable Relative statin initiation rate 
estimates
(95% confidence interval)
Univariable 
model
Multivariable 
model
Sex Male 1 1
Female 0.85 (0.846, 0.855) 0.76 (0.762, 0.772)
Age group 
(years)
18–34 0.03 (0.029, 0.031) 0.029 (0.028, 0.029)
35–49 0.29 (0.286, 0.291) 0.283 (0.281, 0.286) 
50–59 1 1
60–69 1.96 (1.949, 1.979) 1.99 (1.973, 2.002)
70–74 2.44 (2.414, 2.462) 2.48 (2.456, 2.504)
75–84 1.54 (1.522, 1.554) 1.57 (1.552, 1.585)
≥85 0.66 (0.647, 0.676) 0.69 (0.675, 0.705)
Townsend 
score 
quintile
1 (least deprived) 1 1
2 1.03 (1.019, 1.036) 1.05 (1.039, 1.056)
3 0.98 (0.975, 0.991) 1.14 (1.131, 1.150)
4 0.98 (0.971, 0.988) 1.26 (1.251, 1.273)
5 (most deprived) 0.99 (0.979, 0.998) 1.39 (1.372, 1.399)
Notes: In the multivariable model, rates for sex are adjusted for age and Townsend 
score, rates for age groups are adjusted for sex and Townsend score, and rates for 
Townsend score are adjusted for sex and age group.
There were slightly more females than males in the cohort 
(52.2% females and 47.8% males) with the distribution of 
Townsend score quintiles broadly similar to that for the 
cohort in Table 1.
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between 2008 and 2013 of 383.15 to 494.60 for the 75–84 
years group and 232.03 to 390.70 for the 85 years and over 
group. At present, the 70–74 years age group has the highest 
statin prescription rate.
Up to 2007, there was little difference in satin prescrip-
tion prevalence between the five Townsend score quintiles 
(Figure 2D). In 1995, rates varied from 2.15 per 1,000 per-
son years for quintile 5 to 2.48 per 1,000 person-years for 
quintile 3. By 2007, rates for all Townsend score quintiles 
had increased substantially although little difference existed 
between quintiles, with 2007 rates ranging from 94.84 per 
1,000 person-years in quintile 4 to 99.81 per 1,000 person-
years in quintile 2.
In recent years, there appears to be a slight difference 
in prescription prevalence rates, with rates slightly higher 
in more affluent quintiles (quintiles 1 and 2) compared to 
less affluent quintiles (quintiles 4 and 5). In 2013, rates 
for quintiles 1 to 5 (per 1,000 person-years) were 131.12, 
134.13, 125.56, 122.40, and 124.39, respectively. It is of note 
that prescription prevalence rates have increased gradually 
Figure 2 Plots showing the estimated statin prescription prevalence rates from 1995 to 2013. 
Note: (A) Overall, (B) stratified by sex, (C) stratified by age group, and (D) stratified by Townsend score quintile.
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over time for each quintile, with no obvious sharp changes 
in prescription prevalence rates.
Discussion
Findings
The initiation rate of statin therapy increased sharply from 
0.51 per 1,000 person-years in 1995 to 19.83 per 1,000 
person-years in 2006, before declining slowly to a rate of 
10.88 per 1,000 person-years in 2011 and remaining fairly 
steady up to 2013. Similar patterns were seen when initia-
tion rates were stratified by sex, age group, and Townsend 
deprivation score quintile.
It is apparent that the use of statins became more wide-
spread into the 2000s, especially as increasing evidence for 
the effectiveness of statins for the primary prevention of CVD 
became widespread.1–6 In addition, public awareness of the 
importance of low-density lipoprotein cholesterol reduction 
and the use of statins, through the media and health promotion 
campaigns, may have been responsible for a general increase 
in the uptake of statins over time.37 Furthermore, the cost of 
prescribing statins has decreased over time, which may also 
have influenced in the increase in statin therapy initiation.38,39
The peak in statin therapy initiation observed in 2006 
coincides with the NICE recommendation that statins should 
be routinely prescribed for adults with clinical evidence of 
CVD and adults considered to be at risk of CVD and, with 
this, the adoption of the general rule to prescribe statins to 
those whose risk of developing a CVD event within 10 years 
exceeds 20%. As a result, the slow decline in statin initia-
tion rates beyond 2006 may be because a large proportion 
of patients who were eligible for statin therapy had received 
their first statin prescription at this point. Another factor that 
may have influenced the decline in statin therapy initiation 
since 2006 may be the increase in the reporting of the pos-
sible adverse effects of statins.40–42
We saw evidence of a difference in statin initiation rates 
for males and females in recent years, with females initiating 
statins at lower rates than males. The lower rates for females 
may originate from the fact that CVD risk scores, such as 
the Framingham risk score or QRISK score,9,10 are usually 
calculated differently for males and females and, thus, males 
may be more likely to attain a 10-year risk score >20% and 
be prescribed statins. It is well known that CVD events tend 
to occur later for females than for males and that there are 
differences in the prevalence of CVD risk factors.43–46 After 
accounting for age and sex, statin therapy initiation rates 
increased as Townsend score quintile increased, thereby 
implying that the initiation rate of statin therapy increases as 
the level of social deprivation increases. This concurs with 
evidence from another recent study on statin therapy initia-
tion incidence using THIN.47
We observed higher statin therapy initiation rates for 
patients aged 70–74 years, which we would naturally expect 
according to the NICE prescription guidelines for statins. In 
addition, the low initiation rates seen for age groups under 50 
would generally be expected as these are age groups whom 
we would expect to be at the least risk of experiencing a CVD 
event. Generally, the 70–74 years age group had a higher 
statin therapy incidence rate over time than both the 60–69 
years group and the 75–84 years group. It is possible that 
many patients who reach 75 years may already have initi-
ated statin therapy and those in the 75–84 years age group 
who remain eligible for a first statin prescription represent a 
unique, and perhaps more healthy, subgroup of the general 
population. In addition, there have been a limited number 
of randomized controlled trials of the efficacy of statins for 
low-density lipoprotein cholesterol reduction in the over 75s 
and it may be that GPs have not always had clear guidance 
on statin prescriptions for older age groups.48 This may also 
explain why the statin therapy initiation rate is relatively low 
for the 85 years and over age group.
Statin prescription prevalence rates have increased 
smoothly from 1995 to 2001, but more rapidly from 2001 
Table 5 Table showing statin prescription prevalence rates for 
all patients and for males and females separately from 1995 to 
2013 (per 1,000 person-years)
Year Statin prescription prevalence rate
(per 1,000 person years)
All patients Males Females
1995 2.36 2.47 2.25
1996 4.01 4.31 3.74
1997 6.27 6.75 5.82
1998 9.14 9.93 8.41
1999 12.36 13.30 11.50
2000 16.30 17.23 15.43
2001 22.41 23.69 21.21
2002 30.85 32.83 28.99
2003 41.59 44.45 38.90
2004 55.33 58.68 52.17
2005 69.94 74.26 65.85
2006 84.92 90.64 79.51
2007 96.53 103.88 89.57
2008 105.63 114.76 96.99
2009 113.57 124.33 103.37
2010 118.49 130.84 106.79
2011 121.10 134.92 108.08
2012 124.79 139.69 110.79
2013 128.03 143.95 113.12
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to 2009. In recent years, males have had a higher prescrip-
tion prevalence rate than females. Again, this is possibly 
because males tend to be at a higher risk of CVD devel-
opment than females. Prescription prevalence rates are 
broadly similar over time for the different Townsend score 
quintiles, indicating that GP registered patients appear to 
be receiving statin prescriptions at similar rates across 
all levels of socioeconomic deprivation, though there is 
slightly more variation in rates for recent years than in the 
years up to 2007.
We saw smoothly increasing prevalence rates for the 
70–74 years and 75–84 years age groups up to 2009–2010, 
at which point the rate for the 75–84 years group became 
higher than that for the 75–84 years group. This effect is 
perhaps because patients who were prescribed statins in 
their early 70s (the group with the highest statin therapy 
initiation rate) have aged and gradually moved into a higher 
age group over time.
The observed increase in statin prescription prevalence 
from 1995 to 2013 is perhaps what would be expected when 
comparing our results to those from some previous studies. 
Both Teeling et al17 and Walley et al18 reported significant 
increases in the use of statins in Ireland and across Europe, 
in the late 1990s and early 2000s, though we note that these 
studies did not focus solely on the prescription of statins 
for the primary prevention of CVD. In our work, we have 
seen that the use of statins has increased even more rapidly 
between 2003 and 2013.
Strengths and limitations
First, we note that this work is the most recent and compre-
hensive study on statin prescription rates among patients who 
are yet to experience a CVD event using a large database of 
UK primary care records.
A clear strength of this study is the large sample size 
which reflects the general UK population and allows us 
stratify quantities of interest without the problem of small 
group sizes for some strata. In addition, since most GPs 
generate prescriptions electronically, the nature of the 
THIN database allows us to accurately monitor statin pre-
scriptions in a detailed manner, by patient, longitudinally. 
We feel that this has allowed us to make an informed and 
comprehensive assessment of statin prescription rates 
for primary prevention of CVD over time, within the UK 
population.
However, there are limitations to our methods and sample. 
We used data from those who are registered and received 
statin prescriptions from a GP and hence we will not have 
captured those who receive treatment outside primary care. 
We note, though, that the majority of the UK population are 
registered with a GP.49 Some individuals may be initiated 
treatment while they are in hospital; however, the prescribing 
budget lies within primary care. Also, low dose statins can 
be bought over the counter and we would not have captured 
these in our estimates.
Finally, it is important to note that receipt of a statin 
prescription does not necessarily imply that a patient 
actually takes the medication. However, we note that the 
large number of patients who receive repeat prescriptions 
for statins over time is perhaps an indication that these 
patients are actually taking the treatment prescribed on a 
regular basis.
Clinical implications
One clinical question of interest is whether or not statins are 
under- or over-prescribed. Our results would allow clinicians 
to assess whether or not the observed statin prescription rates 
in THIN data are in line with those that would be expected 
for a particular group within the general population who have 
yet to experience a CVD event. As an example, results from 
Abramson et al50 suggested that, in 2011, if CVD risk was 
estimated using the QRISK2 score, then one would expect 2% 
of females and 9% of males in their 50s and 16% of females 
and 48% of males in their 60s to be eligible for regular statin 
prescriptions. Comparatively, our 2011 estimated statin pre-
scription prevalence rates would suggest that, approximately, 
statins were over-prescribed for the 50–59 age group but were 
approximately in line with what would be expected for the 
60–69 years age group.
Final conclusion
The uptake of statins for the primary prevention of CVD 
within UK primary care has increased greatly over time up to 
2013 with statins being more commonly prescribed to older 
patients in general and, in recent years, males appear to have 
been prescribed statins at higher rates than females. After 
accounting for sex and age group, the rate of statin therapy 
initiation is slightly higher as social deprivation level, as 
measured by Townsend score quintile, increases.
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